We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+41.28%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$907M
AUM Growth
+$202M
Cap. Flow
-$185K
Cap. Flow %
-0.02%
Top 10 Hldgs %
41.16%
Holding
93
New
10
Increased
12
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$15.3M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$13.9M
3
KA
Kineta, Inc. Common Stock
KA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$10.9M
5
MTVA
MetaVia Inc
MTVA
+$10M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$30.5M
2
NKTR icon
Nektar Therapeutics
NKTR
+$28.8M
3
SAGE
Sage Therapeutics
SAGE
+$22M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$18.9M
5
NVAX icon
Novavax
NVAX
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
51
DELISTED
Astria Therapeutics
ATXS
$4.93M 0.54%
+13,333
New +$3.51M
INDP icon
52
Indaptus Therapeutics
INDP
$428M
$4.76M 0.53%
362
– –
XLRN
53
DELISTED
Acceleron Pharma
XLRN
$4.61M 0.51%
127,451
– –
OTLK icon
54
Outlook Therapeutics
OTLK
$165M
$4.37M 0.48%
6,420
– –
RIGL icon
55
Rigel Pharmaceuticals
RIGL
$831M
$4.24M 0.47%
+115,560
New +$3.31M
IOVA icon
56
Iovance Biotherapeutics
IOVA
$4.47B
$4.16M 0.46%
505,941
– –
ATRA icon
57
Atara Biotherapeutics
ATRA
$101M
$3.99M 0.44%
7,458
– –
AGRX
58
DELISTED
Agile Therapeutics
AGRX
$3.94M 0.43%
282
– –
SNDX icon
59
Syndax Pharmaceuticals
SNDX
$1.54B
$3.65M 0.4%
240,403
+25,984
+12% +$342K
CRVS icon
60
Corvus Pharmaceuticals
CRVS
$1.03B
$3.52M 0.39%
214,132
– –
LPCN icon
61
Lipocine
LPCN
$17.8M
$3.35M 0.37%
44,194
– –
IMDZ
62
DELISTED
Immune Design Corp.
IMDZ
$3.28M 0.36%
432,990
– –
APTO
63
DELISTED
Aptose Biosciences, Inc.
APTO
$2.23M 0.25%
2,201
– –
RGNX icon
64
Regenxbio
RGNX
$527M
$2.2M 0.24%
156,741
– –
CBIO
65
Crescent Biopharma
CBIO
$638M
$2.05M 0.23%
2,870
– –
NGNE icon
66
Neurogene
NGNE
$694M
$2.03M 0.22%
7,592
– –
CYAD
67
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.79M 0.2%
75,920
– –
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$1.57M 0.17%
159,513
– –
ASND icon
69
Ascendis Pharma A/S
ASND
$16.3B
$1.25M 0.14%
62,254
– –
FOLD
70
DELISTED
Amicus Therapeutics
FOLD
$1.12M 0.12%
151,838
– –
AVEO
71
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$968K 0.11%
108,772
– –
NSTG
72
DELISTED
NanoString Technologies, Inc.
NSTG
$809K 0.09%
40,490
– –
MTEM
73
DELISTED
Molecular Templates, Inc.
MTEM
$686K 0.08%
6,135
– –
ONSIZ
74
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$500K 0.06%
416,666
– –
HTGM
75
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$472K 0.05%
1,130
– –
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Cormorant Asset Management held 93 positions worth $907M, up 29% from $705M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management's Q3 2016 filing shows 10 new, 12 increased, 5 reduced and 9 closed positions. Its largest new stake was Clovis Oncology, Inc.: 650,000 shares worth $23.4M. The largest sale was TESARO, Inc., an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q3 2016 buy was Clovis Oncology, Inc.: 650,000 shares worth $23.4M.
  • Cormorant Asset Management added most to MyoKardia, Inc. Common Stock in Q3 2016, an estimated $15.3M increase.
  • Cormorant Asset Management's biggest Q3 2016 reduction was Alnylam Pharmaceuticals, cutting an estimated $5.24M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q3 2016, selling an estimated $30.5M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $907M portfolio in Q3 2016.
  • Cormorant Asset Management opened 10 new positions and closed 9 in Q3 2016.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $907M.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.